Glaxo's HIV launches continue to shine; U.K. cost watchdog slaps conditions on BMS hep C treatment;

> New GlaxoSmithKline ($GSK) launches--including HIV drugs Tivicay and Triumeq--helped the company offset sliding sales of Advair/Seretide in Q2, it said. Video

> The U.K.'s cost watchdog has restricted use of Bristol-Myers Squibb ($BMY) hep C treatment Daklinza to patients with genotype 1 or 4 who have either had previous drug treatment or who can't receive interferon. Report

> Pfizer's ($PFE) new cancer fighter Ibrance now boasts 22% market share among patients with estrogen-receptor-positive, HER2-negative tumors--up from 10% last quarter, CEO Ian Read said Tuesday. More

> Marina Maher Communications has hired Matthew Anderson as EVP and CMO as its pharmaceutical business continues to expand. Report

And Finally... Fat cartoon characters may make children eat more, a new study says. More

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.